On Jan 5, 2022 SalioGen Therapeutics closed a Series B round and raised $115,000,000 from Cystic Fibrosis Foundation, D1 Capital Partners, EPIQ Capital Group, Fidelity Management and Research Company, GordonMD Global Investments, Retinal Degeneration Fund, SymBiosis LLC, T. Rowe Price, featuring lead investors EPIQ Capital Group, GordonMD Global Investments.

About the company: SalioGen Therapeutics is located at United States, North America.
“The Gene Coding company.”

Company website: http://www.saliogen.com